AmEx Pharmacy is recalling 249 syringes of Bevacizumab (1.25 mg/0.05 mL) because the delivery system is defective, making the medication difficult to express from the syringe. This recall affects one specific lot of the injectable biologic medication that was repackaged into 31G MJ syringes in February 2019. Consumers who may have received this medication for eye conditions should be aware that the mechanical failure of the syringe could interfere with the proper administration of the drug.
A defective delivery system means the syringe may jam or require excessive force to operate, which can lead to an incomplete dose or a traumatic injection experience for the patient. Because this medication is injected directly into the eye (intravitreal), any failure in the delivery mechanism during the procedure could cause patient discomfort or complications during administration.
Standard drug recall remedy
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.